| Attribute |
Value |
| 52 Week Change |
0.27271974 |
| Address1 |
Lichtstrasse 35 |
| All Time High |
170.46 |
| All Time Low |
23.241488 |
| Ask |
0.0 |
| Ask Size |
200 |
| Average Analyst Rating |
2.8 - Hold |
| Average Daily Volume10 Day |
1,962,640 |
| Average Daily Volume3 Month |
1,737,963 |
| Average Volume |
1,737,963 |
| Average Volume10Days |
1,962,640 |
| Beta |
0.495 |
| Bid |
0.0 |
| Bid Size |
200 |
| Book Value |
20.184 |
| City |
Basel |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Switzerland |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
153.37 |
| Current Ratio |
0.848 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
154.17 |
| Day Low |
151.9403 |
| Debt To Equity |
120.734 |
| Dividend Date |
1,773,619,200 |
| Dividend Rate |
4.74 |
| Dividend Yield |
3.08 |
| Earnings Call Timestamp End |
1,777,377,600 |
| Earnings Call Timestamp Start |
1,777,377,600 |
| Earnings Growth |
-0.093 |
| Earnings Quarterly Growth |
-0.125 |
| Earnings Timestamp |
1,784,637,000 |
| Earnings Timestamp End |
1,784,637,000 |
| Earnings Timestamp Start |
1,784,637,000 |
| Ebitda |
22,922,000,384 |
| Ebitda Margins |
0.40514 |
| Enterprise To Ebitda |
14.535 |
| Enterprise To Revenue |
5.889 |
| Enterprise Value |
333,165,068,288 |
| Eps Current Year |
8.69234 |
| Eps Forward |
9.76327 |
| Eps Trailing Twelve Months |
6.95 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,773,187,200 |
| Exchange |
NYQ |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
41 61 324 78 26 |
| Fifty Day Average |
150.354 |
| Fifty Day Average Change |
3.0159912 |
| Fifty Day Average Change Percent |
0.020059267 |
| Fifty Two Week Change Percent |
27.271975 |
| Fifty Two Week High |
170.46 |
| Fifty Two Week High Change |
-17.090012 |
| Fifty Two Week High Change Percent |
-0.10025819 |
| Fifty Two Week Low |
112.34 |
| Fifty Two Week Low Change |
41.03 |
| Fifty Two Week Low Change Percent |
0.36523056 |
| Fifty Two Week Range |
112.34 - 170.46 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
847,377,000,000 |
| Five Year Avg Dividend Yield |
3.53 |
| Float Shares |
1,861,858,897 |
| Forward Eps |
9.76327 |
| Forward P E |
15.708875 |
| Free Cashflow |
12,024,750,080 |
| Full Exchange Name |
NYSE |
| Full Time Employees |
75,267 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.75554 |
| Gross Profits |
42,746,998,784 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0 |
| Held Percent Institutions |
0.07683 |
| Implied Shares Outstanding |
1,908,091,965 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Ir Website |
http://www.novartis.com/investors/index.shtml |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,773,187,200 |
| Last Dividend Value |
4.773 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,554,768,000 |
| Last Split Factor |
1,116:1000 |
| Long Business Summary |
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. |
| Long Name |
Novartis AG |
| Market |
us_market |
| Market Cap |
292,644,061,184 |
| Market State |
PREPRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_382553 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
13,534,000,128 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
293,033,882,496 |
| Number Of Analyst Opinions |
10 |
| Open |
152.68 |
| Operating Cashflow |
19,175,000,064 |
| Operating Margins |
0.30479 |
| Payout Ratio |
0.67910004 |
| Peg Ratio |
4.15 |
| Phone |
41 61 324 11 11 |
| Post Market Change |
1.5700073 |
| Post Market Change Percent |
1.023673 |
| Post Market Price |
154.94 |
| Post Market Time |
1,783,983,466 |
| Previous Close |
154.05 |
| Price Eps Current Year |
17.64427 |
| Price Hint |
2 |
| Price To Book |
7.5985928 |
| Price To Sales Trailing12 Months |
5.1724005 |
| Profit Margins |
0.23921 |
| Quick Ratio |
0.526 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
hold |
| Recommendation Mean |
2.83333 |
| Region |
US |
| Regular Market Change |
-0.680008 |
| Regular Market Change Percent |
-0.44142 |
| Regular Market Day High |
154.17 |
| Regular Market Day Low |
151.9403 |
| Regular Market Day Range |
151.9403 - 154.17 |
| Regular Market Open |
152.68 |
| Regular Market Previous Close |
154.05 |
| Regular Market Price |
153.37 |
| Regular Market Time |
1,783,972,802 |
| Regular Market Volume |
1,061,151 |
| Return On Assets |
0.10541 |
| Return On Equity |
0.34929 |
| Revenue Growth |
-0.007 |
| Revenue Per Share |
29.403 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
1,908,091,965 |
| Shares Percent Shares Out |
0.0028 |
| Shares Short |
5,355,498 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
4,543,531 |
| Short Name |
Novartis AG |
| Short Percent Of Float |
0.0028 |
| Short Ratio |
2.25 |
| Source Interval |
15 |
| Symbol |
NVS |
| Target High Price |
180.0 |
| Target Low Price |
123.0 |
| Target Mean Price |
154.565 |
| Target Median Price |
151.575 |
| Total Cash |
6,892,000,256 |
| Total Cash Per Share |
3.612 |
| Total Debt |
46,997,999,616 |
| Total Revenue |
56,577,998,848 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
4.666 |
| Trailing Annual Dividend Yield |
0.030288866 |
| Trailing Eps |
6.95 |
| Trailing P E |
22.067625 |
| Trailing Peg Ratio |
4.1539 |
| Triggerable |
1 |
| Two Hundred Day Average |
144.30286 |
| Two Hundred Day Average Change |
9.067139 |
| Two Hundred Day Average Change Percent |
0.06283409 |
| Type Disp |
Equity |
| Volume |
1,061,151 |
| Website |
https://www.novartis.com |
| Zip |
4,056 |